oruvestat

Oruvestat (VTG-001) is an orally bioavailable, potent, and selective small molecule inhibitor of Vascular Adhesion Protein-1 (VAP-1), also known as Amine Oxidase Copper Containing 3 (AOC3). VAP-1 is a dual-function protein acting as both an adhesion molecule and a semicarbazide-sensitive amine oxidase (SSAO) enzyme that facilitates leukocyte recruitment to inflamed tissues. By inhibiting the enzymatic activity of VAP-1, oruvestat reduces the inflammatory response and subsequent fibrosis, positioning it as a therapeutic candidate for inflammatory and fibrotic conditions. Originally developed by Pharmaxis as PXS-4728A and previously licensed to Boehringer Ingelheim as BI 1467335, the asset was acquired by Vantage Biosciences for development in non-proliferative diabetic retinopathy (NPDR), metabolic dysfunction-associated steatohepatitis (MASH), and primary sclerosing cholangitis (PSC).

Other names

oruvestat